SAN ANTONIO, Texas--(BUSINESS WIRE)-- Tissue Regenix (AIM:TRX) (‘Tissue Regenix’ or ‘The Group’) the UK based regenerative medical devices company announces subsidiary CellRight Technologies (‘CellRight’) will be participating in The North American Spine Society annual meeting - NASS 2017, being held in Orlando, Florida, October 25-28 2017.

NASS is the largest spine exhibition in the world where spine care professionals from around the globe will share the latest information on new technologies, innovative techniques and procedures, and best practice.

NASS is the first conference that the Group have attended since completing the acquisition of CellRight Technologies in August. The Group will be exhibiting at booth #1343 promoting its range of products including Matrix OI® stem cell containment products, MatrixCellect 100 DBM putty, ConCelltrate Inductive Carrier Matrix and Matrix OI Cortical Fibers.

CellRight is focused on innovative product development expanding the potential of regenerative solutions in the osteobiologics field, offering surgeons and patients a biologic product portfolio.

With products that are 100% allograft bone, the innovative platform technology preserves the native Bone Morphogenic Proteins (BMPs) and growth-factors to verify osteoinductivity needed for bone regeneration, resulting in best-in-class products and ensuring superior clinical outcomes. CellRight verifies osteoinductivity for every lot post sterilization and these osteogenic bioengineered implants address indications in the spine, trauma, TJA and sports medicine fields.

The CellRight technology complements dCELL® Technology, Tissue Regenix’ patented decellularization process for soft tissues. In due course, soft tissue products for use in various orthopedics applications, with an initial focus on ligament reconstruction, will also be processed at the state-of-the-art CellRight tissue bank facility based in San Antonio, Texas.

Jesus Hernandez, CEO CellRight Technologies commented: “We are delighted to be attending NASS as part of the larger Tissue Regenix Group. This conference offers a unique opportunity to showcase our portfolio of innovative spinal products and discuss the future potential of the combined CellRight and dCELL® platforms with some of the best healthcare specialists in the world.”

###

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company’s patented decellularisation (‘dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - ‘Tissue Regenix Wound Care Inc.’, January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171024006526/en/